Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma (NHL): a phase III randomised clinical trial (Intergrou...

Update Il y a 4 ans
Reference: ISRCTN65655917

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma (NHL): a phase III randomised clinical trial (Intergroup Collaborative Study)

Woman and Man

Extract

Not provided at time of registration


Inclusion criteria

  • Lymphoma (non-Hodgkin's)


Links